Fluoroquinolone derivatives interact with methylxanthines (theophylline, caffeine) and metallic ion-containing drugs to different degrees. The rat appears to be a suitable model for predicting such interactions in man. It has been possible to determine the relationship between the chemical structure of the fluoroquinolone and the magnitude of the interaction. Fluoroquinolones with a bulky substituent at the position 8, such as sparfloxacin, lomefloxacin and fleroxacin, are less prone to interact with theophylline than those without an 8-substituent, such as enoxacin. This substituent determines the planarity of the whole fluoroquinolone molecule and the interaction tends to be more significant for planar fluoroquinolones. Furthermore, a 4'-nitrogen atom in the 7-piperazinyl group is essential for the interaction to occur. The nitrogen atom is possibly the site that binds cytochrome P-450, which catalyses theophylline metabolism. The reduction in bioavailability of fluoroquinolones by concurrent administration of aluminium hydroxide is more striking for derivatives with fewer substituents on the essential structure and on the piperazinyl group, such as norfloxacin, ciprofloxacin and enoxacin. Substitution at the 5-position diminishes the interaction, which suggests that the 5-substituent may affect the formation and/or stability of unabsorbable chelate complex which is the probable cause of the interaction. These findings are potentially useful in designing fluoroquinolones less prone to drug interactions.
Introduction
The fluoroquinolone antibacterial agents are characterised by a broad antibacterial spectrum, good oral absorption and wide tissue distribution. They have become widely used in the treatment of a number of infectious diseases. However, as their clinical use has increased, so have the number of reports of drug interactions, some of which have serious clinical consequences. These include pharmacokinetic interactions, such as the inhibition of quinolone absorption by metallic cation-containing compounds (e.g. antacid and vitamin preparations), and the inhibition of the metabolism of methylxanthines (theophylline and caffeine); pharmacodynamic interactions, such as induction of convulsions by the non-steroidal anti-inflammatory drug fenbufen; and physicochemical interactions due to incompatibilities between quinolones, such as pefloxacin and ciprofloxacin, and some penicillin antibiotics (Davey, 1988; Wijnands & Vree, 1988; Janknegt, 1990) . In contrast, there have been few reports of drug interactions with sparfloxacin, since its availability in Japan. Compared with other fluoroquinolones currently available, sparfloxacin is more active against Gram-positive bacteria, chlamydiae and mycobacteria (Nakamura et al., 1989) . It also has a favourable pharmacokinetic profile including good tissue distribution and a long half-life (Shimada, Nogita & Ishibashi, 1993) . These properties can be attributed to particular aspects of its structural formula (Andriole, 1993) . Similarly, the structure activity properties of a quinolone influences its propensity to interact with other drugs. This review focuses on the pharmacokinetic interactions of fluoroquinolones, including sparfloxacin, with methylxanthines (theophylline and caffeine) and aluminium hydroxide.
Methylxanthines

Theophylline
Studies in humans. Concomitant administration of enoxacin and theophylline was reported to cause headache and abdominal discomfort (Maesen et al., 1984; Wijnands, Van Herwaarden & Vree, 1984) . Subsequently, enoxacin was found to decrease the theophylline clearance, leading to increased plasma theophylline concentrations (Wijnands, Vree & Van Herwaarden, 1985) . Thereafter, ciprofloxacin, pefloxacin (Wijnands, Vree & Van Herwaarden, 1986 ) and tosufloxacin (Niki et al., 1988a) were also reported to increase plasma or serum theophylline concentrations, although no marked clinical symptoms were noted. A weak interaction with theophylline, without accompanying clinical effects, was also found for both ofloxacin and norfloxacin (Niki et al., 1987 ), yet no significant interaction with theophylline were detected for lomefloxacin (Niki et al., 1988*) , fleroxacin (Niki et al., 1990) and sparfloxacin (Okimoto et al., 1991) . The structures of these fluoroquinolones are shown in Figure 1 .
Theophylline is primarily eliminated by hepatic metabolism to 3-methylxanthine (3-MX), 1-methyluric acid (1-MU) and 1,3-dimethyluric acid (1,3-DMU), which are mainly excreted in the urine (Grygiel & Birkett, 1980) . Rogge et al. (1988) reported that concurrent administration of enoxacin with theophylline resulted in a significant decrease in the urinary excretion of these three metabolites. However, co-administration of fleroxacin or sparfloxacin, which had no influence on plasma concentrations of theophylline as described above, resulted in no significant change in the urinary concentrations of theophylline metabolites (Niki et al., 1990; Yamaki et al., 1991) .
Using a NADPH-generating system, Sarkar et al. (1990) examined the effect of several fluoroquinolones on the in-vitro metabolism of theophylline by the human liver microsome fraction. The yield of each theophylline metabolite was lowest with enoxacin (the extent of the inhibition was 3-MX > 1-methylxanthine (an intermediate to 1-MU > 1,3-DMU), intermediate with ciprofloxacin and highest with norfloxacin. These results concur with the degree of interaction reported in vivo with these agents. These findings indicate that the interaction between fluoroquinolones and theophylline is the result of inhibition of cytochrome P-450.
Studies in rats. We have examined the mechanism of the theophylline-quinolone interaction using a rat model (Mizuki et al., 1989 (Mizuki et al., *, 1991 . When the extent of the fluoroquinolone-theophylline interaction was assessed by their effects on the elimination half-life (t{) of theophylline, the quinolones could be ranked as follows: enoxacin > ciprofloxacin > norfloxacin > ofloxacin > sparfloxacin (Table I) , which essentially reflects the order of magnitude of the interaction in humans. Therefore, the rat appears to be a suitable model for predicting this interaction in man. Table I . Plasma elimination half-lives (T\) of theophylline after single oral administration (15 mg/kg) in rats treated with various fluoroquinolones 2 h before, and 2 h and 6 h after the theophylline dose, and comparison of increases in calculated peak plasma concentration (C™,) at steady state in rats with observed (CM, of theophylline in humans (Mizuki et al., 19896) •The doses of the fluoroquinolones were adjusted so that their peak plasma concxntrations ranged from 5 to 10 mg/L. *Each tj value is the mean ± S.E.M. for five animals. The C», increases in humans were reported by 'Niki el al. (1987) and AVijnands, Vree & Van Herwaarden (1986) .
Unchanged theophylline, 1-MU and 1,3-DMU are excreted in the urine of rats given theophylline. Co-administration of enoxacin with theophylline caused a significant increase in the urinary excretion of unchanged theophylline and a significant decrease in the two metabolites . However, no changes were observed when sparfloxacin was co-administered with theophylline in this model (Mizuki et al., 1991) . Inhibition of theophylline metabolism by enoxacin has also been demonstrated in vitro using the isolated rat liver cell system; the inhibition was greater than that seen with ofloxacin (Mulder et al., 1988) .
Relationship between interaction and chemical structure. Using the rat model, an attempt has been made to relate the chemical structure of fluoroquinolones with their propensity to interact with theophylline (Table II) . Quinolones with a bulky substituent at position 8, e.g. fluoro or methoxy group (derivatives nos 1-11), were less prone to interact with theophylline than those with a hydrogen at position 8 (derivatives nos 12-15) which in turn were less likely to inhibit the metabolism of theophylline than quinolones with no substituent at position 8 (derivatives no. 16 and no. 17). In contrast, the substituent at either position 1 or 5 and the position and number of methyl groups 1.68
•The doses of the derivatives were adjusted so that their maximum plasma concentrations ranged from 5 to lOmg/L.
'Mean tj during coadministration/mean control tj (n = 4 or 5). 'Naphthyridine:
in the piperazine ring at position 7 were found to scarcely affect the degree of interaction.
The results of in-vitro metabolic studies are presented in Table III . An enoxacin derivative which lacks the carboxyl group at position 3 (no. 24) had equivalent inhibitory activity to enoxacin (no. 16) whereas a derivative which lacks the terminal nitrogen atom in the 7-piperazinyl group of enoxacin (no. 25) demonstrated no inhibitory activity . Similarly, derivatives which have a carbonyl group at a neighbouring position to the terminal nitrogen atom (no. 26 & 27) showed minimal inhibitory activity (unpublished data).
Our previous studies of the inhibitory effect of different quinolone substrates on rat liver microsomal enzymes suggested that the nitrogen atom is the portion that binds to the trivalent iron ion (Fe 3 + ) (Poulos et al., 1985) in the catalytic centre of cytochrome P-450. Being electrophilic, Fe 3+ is capable of binding basic functional groups (Dawson, Andersson & Sono, 1982) , such as a nitrogen atom, at the sixth ligand. This binding could hinder the approach of theophylline to the active centre of cytochrome P-450, resulting in reduced theophylline metabolism. When the carbonyl group was introduced adjacent to the nitrogen, the basicity of the nitrogen disappeared due to the electron-attracting effect of the carbonyl group and hence the affinity between the nitrogen and Fe 3+ possibly decreased. This hypothesis was strongly supported by the electrostatic potential distribution calculated by the molecular orbital method. Figure 2 illustrates the isopotential contours of enoxacin (no. 16) and its 3'-oxo derivative (no. 26), which has a carbonyl group adjacent to the nitrogen. The isopotential shape of derivative no. 26, which exhibited less of an inhibitory effect 3'-oxo-enraacin 26
Figure 2. Electrostatic potentials of 3'-oxo-enoxacin (no. 26) and enoxacin (no. 16) based on the AMI molecular orbital calculation (Mizuki et al., 1996) . Lines in shadowed and open areas represent an isopotential contour at -I and + 1 kcal/mole, respectively.
in vitro compared with enoxacin, obviously differs from enoxacin around the nitrogen, i.e. the potential Fe 3 * binding site (Mizuki et al., 1996) . In addition, the substituent at position 8 was found to affect the degree of interaction between theophylline and fluoroquinolone. Derivative no. 11, which has a fluorine atom at position 8, showed only a weak interaction with theophylline (Table II) despite having similar physicochemical properties (e.g water solubility, log P and pKa), pharmacokinetic properties in rats, and electrostatic potentials to those of enoxacin (no. 16) (data not shown). When the stereochemistry of these two compounds was studied by X-ray crystallography and by the molecular orbital method, enoxacin was found to have a highly planar conformation, since its essential skeleton naphthyridine ring was present on the same plane as the piperazine at its 7 position (Figure 3 ).
Derivative no. 11, on the other hand, exhibited steric hindrance between its essential skeleton quinolone ring and its piperazine substituent, which resulted in a lack of planar conformation ( Figure 3) (Mizuki et al., 1996) . Miyamoto et al. (1990) reported X-ray crystallographic data on sparfloxacin (no. 1), which possesses a fluorine atom at position 8 and exhibited no interaction with theophylline (Table II) , showing that the compound had a bulky conformation toward the quinoline plane similar to derivative no. 11. The steric conformation of pefloxacin (no. 14), based on X-ray crystallography (Baenziger, Fox & Modak, 1986) , and norfloxacin (no. 13) calculated from pefloxacin data (data not shown), estimated their bulkiness as intermediate between enoxacin and sparfloxacin. This correlates with the degree to which these agents interact with theophylline (Table II) . These results suggest that it is necessary for the quinolone to have a planar conformation in order to approach cytochrome P-450, bind to Fe 3 + and inhibit theophylline metabolism. The conformation of theophylline has also been reported to be highly planar (Sutor, 1958) .
The above discussion has focused on fluoroquinolones with a 7-piperazine group but according to our study results, it also holds true for fluoroquinolones which have a 7-pyrrolidine substituted with an amino group (unpublished data, see Table II ).
Caffeine
Although adverse symptoms are clinically less obvious, the plasma or serum t| of caffeine, like that of theophylline, is prolonged by concurrent administration of certain fluoroquinolones. The likelihood of an interaction with caffeine has been 8-fluorinated derivative 11 Enoxacin 16 Figure 3 . Molecular structures of 8-fluorinated derivative (no. 11) optimised by the AM 1 molecular orbital calculation and enoxacin (no. 16) based on X-ray crystallography (Mizuki et al., 1996) .
Pharmacoklnetic interactions of fluoroqulnolones 49 ranked as follows: enoxacin > ciprofloxacin = norfloxacin > ofloxacin = lomefloxacin (Fuhr et al., 1992a) , which is similar to the situation for theophylline. By conducting in-vitro studies on caffeine metabolism in human liver microsome preparation to yield paraxanthine (3-N-demethylation) and 1,3-dimethylxanthine (7-N-demethylation), Fuhr et al. (1990) have shown that the cause of the interaction is competitive inhibition of caffeine metabolism by fluoroquinolones. Therefore, the relationship between chemical structure and the degree of interaction is thought to be the same as for theophylline. The enzyme CYP1A2 has been shown to be involved in the metabolism of caffeine (Butler et al., 1989; Berthou et al., 1991; Fuhr et al., 1992A) . Fluoroquinolones have only been reported to have a marked metabolic interaction with methylxanthine drugs, which suggests that fluoroquinolones specifically inhibit CYP1A2.
Metallic cation-containing compounds
Aluminium hydroxide Studies in humans. When fluoroquinolones are administered orally concurrently with aluminium hydroxide, the plasma or serum concentration and urinary recovery of fluoroquinolone are decreased as a result of decreased bioavailability. Shimada et al. (1991) compared the peak serum concentrations, AUCs and urinary recovery of fluoroquinolones administered to healthy volunteers at a dose of 200 mg both with and without aluminium hydroxide 1 g. The magnitude of interaction was least for sparfloxacin and fleroxacin, intermediate for ofloxacin and lomefloxacin, and greatest for norfloxacin and enoxacin. In an earlier study, the AUC of ciprofloxacin 750 mg was 84.5% lower after co-administration with aluminium hydroxide 2.4 g (Frost et al., 1989) . Thus, it appears that, similar to the situation with theophylline, the degree of interaction between aluminium hydroxide and the quinolone is dependent upon the chemical structure of the quinolone.
Chelate formation involving metallic ions and 3-carboxyl and 4-carbonyl groups on the quinolone, leading to inhibition of quinolone absorption, has been proposed as the cause of the interaction (Polk, 1989) . This concept was seemingly based on the reports that nalidixic acid, which possesses these functional groups, interacted with various metallic ions and this resulted in changes in its physicochemical properties (UV spectrum, partition ratio to carbon tetrachloride and permeability to artificial membrane) (Nakano, Yamamoto & Arita, 1973; Coif, Goodfield & Williams, 1984) . Through the use of 13 C-NMR, Shimada et al. (1992) revealed that the 3-carboxyl and 4-carbonyl groups of lomefloxacin played a role in its interaction with Al 3 + and Mg^+ ions.
Studies in rats. Compared with rats given enoxacin, ofloxacin or norfloxacin 20 mg/kg alone, the AUC and urinary recovery of each fluoroquinolone were significantly lower in rats concomitantly given aluminium hydroxide 50 mg/kg (Okazaki, Kurata & Tachizawa, 1988) . The degree of decrease was in the order of norfloxacin > enoxacin > ofloxacin. The amount of ofloxacin remaining in the digestive tract was greater when the quinolone was co-administered with aluminium hydroxide and thus the fraction absorbed was lower. Ofloxacin and norfloxacin were found to form a stable chelate complex with Al 3 + .
In a similar study, rats were given 20 mg/kg of various fluoroquinolones with or without aluminium hydroxide 100 mg/kg and the fluoroquinolone AUC calculated (unpublished data). The decrease in AUC with co-administration of aluminium hydroxide ranged from 9 to 69% and the ranking of the magnitude of the interaction was norfloxacin = ciprofloxacin > enoxacin > ofloxacin > lomefloxacin > sparfloxacin (Table IV) , which corresponded to the degree of interaction observed in healthy human volunteers. Therefore, the rat appears to be a useful model for studying this interaction.
Relationship between interaction and chemical structure. To elucidate the relationships between chemical structure and interaction with aluminium hydroxide, various fluoroquinolone derivatives were administered alone and with aluminium hydroxide to rats and the fluoroquinolone AUCs calculated ( Table V) . The major findings were: (i) the interaction is less significant for derivatives with a naphthyridine ring rather than COOH a quinoline ring; (ii) a cyclopropyl group at position 1 rather than an ethyl group decreases the likelihood of interaction; (iii) a 3-carboxyl group is essential for the interaction; (iv) the presence of a substituent at position 5 lessens the interaction; (v) a methyl group in the 7-piperazine ring weakens the interaction; (vi) the interaction occurs even in the absence of a 7-substituent; and (vii) an 8-fluoro group decreases the extent of the interaction. The important conclusion is that the more substituents there are in the essential skeleton and the piperazine group, the less significant the interaction. In addition, point (iii) supports the view that the interaction is caused by chelation involving substituents at positions 3 and 4. A significant positive correlation was observed between the stability constants, measured by potentiometric titration of the chelate of fluoroquinolones with Al 3 + , and decreases in AUC (Table V & Figure 4 ). This indicates that the greater the stability of the chelate, the more significant the interaction and suggests that the chelate is minimally absorbable. Two derivatives with a 5-amino group, including sparfloxacin, were off the correlation line negative to the y-axis (Figure 4) , indicating that the interaction with these derivatives was less significant despite the stability of their chelates. This may suggest that the chelate of the 5-amino derivatives has essentially different properties to the chelates with other derivatives.
Iron and calcium-containing drugs
Metallic cation-containing drugs other than aluminium hydroxide, including ferrous sulphate, ferrous-glycine-sulphate and calcium carbonate have been reported to interact with fluoroquinolones. These metals also form a chelate complex with fluoroquinolones.
When co-administered with fluoroquinolones in humans, Fe 2 + -containing drugs decreased the AUC of ciprofloxacin, ofloxacin (Lode et al., 1989) , norfloxacin and sparfloxacin (Kanemitsu et al., 1994) with the control. Although these studies were not performed under the same conditions and therefore direct comparisons are difficult, it appears that the degree of interaction is high for ciprofloxacin and norfloxacin and low for the other fluoroquinolones. The extent of the interaction with Fe 2 + -containing drugs seems to be similar to or slightly lower than that with Al 3 + -containing drugs. The interaction between fluoroquinolones and Ca 2 + -containing drugs appears to be less significant than that with other metallic cations; calcium carbonate administered 5 min before ingestion of ciprofloxacin (Frost et al., 1992) or 2 h before norfloxacin (Flor et al., 1990) lowered the AUC of the quinolone by only 42 and 4%, respectively, compared with the control.
In rats, the sparfloxacin AUC was found to decrease by 15% and 0% when co-administered with ferrous sulphate (100 mg/kg) or calcium gluconate (200 mg/kg), respectively, whereas the enoxacin AUC was 51% and 7% lower, respectively. The highest stability constants of the chelate between the metallic ion and the two quinolones were observed with Al 3+ followed by Fe 2 * and then Ca 2 + , which corresponds well with the degree of interaction observed in vivo. As above, the formation of the chelate complex conceivably plays an important role in the interaction between the quinolones and metallic cation-containing drugs. However, it has not yet been possible to fully elucidate the relationship between the chelate and the number of substituents on the essential structure of the fluoroquinolone and on the piperazinyl moiety. For an overview of absorption interactions with fluoroquinolones, see Lomaestro & Bailie (1995) .
Conclusions
Fluoroquinolone derivatives interact with methylxanthines (theophylline, caffeine) and metallic ion-containing drugs to different degrees. The rat appears to be a suitable model for predicting the magnitude of these interactions in man. The stereochemistry and the electron density distribution of fluoroquinolones are important determinants of the interaction with theophylline. Sparfloxacin, which has a bulky substituent at position 8 and therefore lacks a planar conformation, does not appear to inhibit the metabolism of theophylline significantly and thus no specific precautions are required for patients who receive both drugs concomitantly. This is of importance for a quinolone used in the treatment of respiratory tract infections.
As regards metallic cation-containing drugs, the stability of the chelate with the fluoroquinolone is an important determinant of the degree of interaction. The decrease in fluoroquinolone absorption appears to be greatest with Al 3 + -containing preparations followed by Fe 2 + -and then Ca 2 + -containing compounds. These findings are potentially useful when designing fluoroquinolones less prone to drug interactions.
